All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Achieve Life Sciences Q3 net loss and loss per share beat estimates

By Reuters News


Overview

  • US pharmaceutical firm's Q3 net loss and loss per share both beat analyst expectations

  • Q3 operating loss narrowed, beating analyst expectations

  • NDA resubmission for cytisinicline on track for Q4 2026, with possible FDA approval in 2027


Outlook

  • Company expects NDA resubmission for cytisinicline in Q4 2026

  • Company anticipates potential FDA approval by end of Q2 2027

  • AchieveRx plans U.S. commercial launch of cytisinicline following FDA approval, if granted


Result Drivers

  • CLINICAL RESULTS - Co said ORCA-OL trial data showed rising quit rates and no new safety signals for cytisinicline

  • MANUFACTURING PROGRESS - Co completed three commercial-scale stability batches for cytisinicline, supporting NDA resubmission timeline

  • LEADERSHIP EXPANSION - Co expanded launch team with two senior appointments as it prepares for commercialization


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

Beat

$0.11

$0.20 (12 Analysts)

Q3 Net Loss

Beat

$12.11 mln

$19.30 mln (9 Analysts)

Q3 Income From Operations

Beat

-$20.54 mln

-$22.79 mln (9 Analysts)

Q3 Operating Expenses

$20.54 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Achieve Life Sciences, Inc. is $12.50, about 84.4% NOT AVAILABLE its November 9 closing price of $6.78


Reuters Recommended Reads

  • Nov 9 - Canada's Xenon Pharmaceuticals posts smaller-than-expected Q3 net loss

  • Nov 9 - Annexon Biosciences Q3 net loss narrows on lower R&D expenses, cash runway extends to 2028

  • Nov 9 - TG Therapeutics Q3 product revenue rises on BRIUMVI sales; lifts 2026 outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.